Skip to content
Tenfell
Awarded contract
Published 12 Aug 2022

NHS Framework Agreement for South of England Branded - Tranche B and Annual

NHS England · London

Key facts

Awarded
14 Jul 2022
Contract starts
31 Aug 2022
Contract ends
31 Aug 2024
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 29 suppliers

SupplierValue
Takeda UK Limited—
Almirall Ltd—
CST Pharma Ltd—
GlaxoSmithKline—
Janssen-Cilag Ltd—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Aventis Pharma Ltd T/A Sanofi—
Sandoz Ltd—
Thornton & Ross Ltd—
Typharm Ltd—
Accord-UK Ltd—
AstraZeneca—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Ipsen—
Merck Serono Limited—
Merck Sharpe & Dohme (UK) Limited—
Mylan—
Novo Nordisk—
Organon Pharmaceuticals UK Ltd—
Roche Products Ltd—
Sobi (Swedish Orphan Biovitrum Ltd)—
Zentiva Pharma UK Ltd—
UCB Pharma Ltd (primary)—
UL Global Pharma—

Description

NHS South of England Branded Medicines - Tranche B

Offer reference number: CM/PHR/20/5611

CM/PHR/20/5611/01 - NHS Framework for SOUTH of England Branded Medicines - Tranche B. Period of framework: 1 September 2022 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5611/02 - NHS Framework for the SOUTH of England Branded Medicines - Annual Tranche. Period of framework: 1 September 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.